Replies to post #300673 on Anavex Life Sciences Corp (AVXL)

[vg_future]

Thanks MayoMobile for capturing the notes. Great nuggets.

-vg_future

[toemind]

Mayo,
Many thanks for your detailed description of AVXL's talk at today's conference! Very encouraging again.
I like the reference to an upcoming peer-reviewed journal article regarding activation of the SIGMAR1R receptor.
Misslings's answer to the last question regarding Biogen seemed like quite a deft reply.
Thanks again for your detailed efforts.
It is hard to wait, but wait we must.
ToeMind

[georgejjl]

MayoMoblie, I agree 100%

PDD is a phase 2/3 pivotal study, and POTENTIALLY PD will be pivotal as well (that's new info)

Full U.S. Rett Syndrome phase 2 study data and full PDD data due late 1st quarter or early 2nd

Expect full PDD trial results and full US Rett syndrome trial results within the next month or two. (before May 2021)

WATCH and LISTEN regarding Anavex (AVXL)

https://wsw.com/webcast/svbleerink47/register.aspx?conf=svbleerink47&page=avxl&url=https://wsw.com/webcast/svbleerink47/avxl/2676736

Good luck and GOD bless,

[HMB2010]

Thank you.

[512]

Thanks!!:)

[powerwalker]

Mayo, thank you for that summation. Hope we learn of the trials' results before the AGM in April.



ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!

[falconer66a]

Exact, precise summary of Missling's presentation.

MayoMobile, thank you for presenting this very accurate listing of Christopher Missling's presentation points. It is worth considering each of these listed points of fact; they indicate where Anavex Life Sciences Corp is headed.

I listened intently to Missling's discussion. His laying out of the Anavex science comported exactly with what I knew about it. It is strong, wide, deep, new, and innovative.

Like others, I was delighted to learn more of the details where and how the various trials will proceed.

Most important were the clinical trial data he presented. Of course, they are not yet complete, but in every case they point to extremely strong clinical readouts later in the year. Solid, through and through.

Since I took my first small AVXL position about five years ago I've continued to scrutinize all of the Anavex science that I could find. Back then, most of it derived from murine (lab rodent) studies; which I carefully projected on up to humans. That's not always a wise or accurate thing to do. Mice aren't men, at least in many respects.

But as a biologist familiar with cytology and cellular biochemistry I could see that the Anavex sigma-1 receptor activation in lab rodents with transgenic human diseases, yielding propitious therapeutic resolutions, would happen later in humans, too. Everything Missling indicated confirmed that informed conjecture. Anavex science at work in humans, with a wide diversity of diseases and conditions, is no longer anyone's conjecture. The trials' readouts later in the year will thoroughly squelch whatever Anavex naysaying that might yet persist.

The next two or three years are going to be very exciting, for both those who hold AVXL positions, and for the multitude of people who will be successfully treated with the Anavex sigma-1 receptor activators.

[Pipilongstocking]

Thanks for the good summary.

[mrplmer]

Mayo- Thanks for the summary.

[nidan7500]

MayoMobile...clearly an "Above and Beyond effort" here. Just exceptional. MY GUESS is the MJF people must be delighted w/AVXL and A2-73 deliverables. They have here, the real truth about PDD. EXCELLENT STUFF.

- PDD is a tough indication, three failures recently across the industry. PDD has multiple pathologies which makes it so hard to treat. Our data is intriguing because we had a strong signal across the patients. All domains will be readout in the upcoming data release. Dose-dependent improvement in PDD, 30mg stopped decline, 50 mg improved patient. The 50mg patients "came out of the study with less dementia". 70% of this data has direct correlation with ADAS-COG (AD primary endpoint). REM was also improved and so was digital vigilance and episodic memory. No safety issues.

[attilathehunt]

kudos....nice recap!!